Delivery Order SPE2DR25D2006-SPE2DR26F55VW
Award Date 11/3/25
Potential Completion Date 11/4/25
Potential Value $54K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $139,894.18 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,527.44 delivery order on September 19, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, non-set-aside contract with a completion date of September 22, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $3,298.76 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on October 24, 2025, with completion scheduled for October 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $1,263.72 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $1,684.96. This is a firm fixed-price delivery order with no set-aside designation, issued as a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion pharmaceutical prime vendor agreement running through December 2026. The product will be delivered...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $3,228.20 with a completion date of August 29, 2025. This delivery order represents a firm fixed-price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $134,719.00 on August 27, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency (DLA) awarded a $72,453.28 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with an ultimate completion date of October 22, 2025. This is a firm fixed-price delivery order issued under a non-competitive set-aside structure. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems....